Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
They Wanted a Quick Fix for Hair Loss. Instead, These Young Men Got Sick.
Hims and other telehealth firms make finasteride easy to get and don’t have to disclose side effects in ads.
FDA update could extend Hims & Hers’ compounding timeline, says BofA
BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...
Hims and Hers bought a skincare startup for $190 million 4 years ago. Today they shut it down.
Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Analysts Have Mixed Reviews on Hims & Hers Stock Amid Uncertainty Around Weight Loss Business
Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...
Novo Nordisk offers Wegovy at lowered cost, Hims & Hers Health shares fall
Novo Nordisk (NYSE:NVO) is introducing NovoCare Pharmacy, a direct-to-patient delivery option offering Wegovy at a reduced price of $499 per month for certain cash-paying patients.
Hims & Hers: A Generational Dip-Buying Opportunity
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Eli Lilly takes aim at weight-loss drug copies with new ad campaign
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...
The GLP-1 Revolution — How Private Equity Investors Are Capitalizing
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Hims & Hers will stop selling some weight loss drugs — and the stock plummets 27%
Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused telehealth company reported soaring sales for 2024 just the night before.
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth provider's lofty sales forecast on Tuesday amid looming restrictions on ...